Lymphoplasmacytic lymphoma classification: Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*Symptomatic [[Waldenstrom macroglobulinemia]] | *Symptomatic [[Waldenstrom macroglobulinemia]] | ||
*Asymptomatic/Smoldering [[Waldenstrom macroglobulinemia]] (SWM)<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119 }} </ref> | *Asymptomatic/Smoldering [[Waldenstrom macroglobulinemia]] (SWM)<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119 }} </ref> | ||
{| | {| | ||
|+ '''Classification of WM and Related Disorders''' | |+ '''Classification of WM and Related Disorders''' | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria | ||
| Line 18: | Line 18: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS | ||
|- | |- | ||
! style="background:#DCDCDC; | ! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| Line 24: | Line 24: | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
|- | |- | ||
! style="background:#DCDCDC; | ! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| Line 30: | Line 30: | ||
| style="background:#F5F5F5;" align="center" + | - | | style="background:#F5F5F5;" align="center" + | - | ||
|- | |- | ||
! style="background:#DCDCDC; | ! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| style="background:#F5F5F5;" align="center" + | - | | style="background:#F5F5F5;" align="center" + | - | ||
| Line 36: | Line 36: | ||
| style="background:#F5F5F5;" align="center" + | - | | style="background:#F5F5F5;" align="center" + | - | ||
|- | |- | ||
! style="background:#DCDCDC; | ! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration | ||
| style="background:#F5F5F5;" align="center" + | + | | style="background:#F5F5F5;" align="center" + | + | ||
| style="background:#F5F5F5;" align="center" + | - | | style="background:#F5F5F5;" align="center" + | - | ||
Revision as of 15:42, 20 February 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma classification On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma classification |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into smoldering/asymptomatic and symptomatic WM .
Classification
There is no established system for the classification of lymphoplasmacytic lymphoma. However, according to a devised criteria based upon patient's symptoms, Waldenström's macroglobulinemia can be further classified into:[1]
- Symptomatic Waldenstrom macroglobulinemia
- Asymptomatic/Smoldering Waldenstrom macroglobulinemia (SWM)[2]
| Criteria | Symptomatic WM | Asymptomatic WM | IgM-Related Disorders | MGUS |
|---|---|---|---|---|
| IgM monoclonal protein | + | + | + | + |
| Bone marrow infiltration | + | + | - | - |
| Symptoms attributable to IgM | + | - | + | - |
| Symptoms attributable to tumor infiltration | + | - | - | - |
References
- ↑ Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
- ↑ Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M; et al. (2003). "Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia". Semin Oncol. 30 (2): 116–20. doi:10.1053/sonc.2003.50038. PMID 12720119.